Cyclo (-RGDfC): High-Affinity αvβ3 Integrin Targeting Peptide for Cancer and Angiogenesis Research

Executive Summary: Cyclo (-RGDfC), also known as c(RGDfC), is a cyclic RGD peptide engineered for high-affinity binding to the integrin αvβ3 receptor—a critical target in tumor and angiogenesis research (APExBIO). The peptide’s circular structure enhances its stability and selectivity, with >98% purity validated by HPLC and MS. Cyclo (-RGDfC) is insoluble in water and ethanol but dissolves at ≥49 mg/mL in DMSO. It is widely used in integrin-mediated cell adhesion, migration, and signaling pathway studies, and supports diverse conjugation strategies for targeted delivery applications (America Peptides). The product is rigorously controlled for quality and intended for research use only.

Biological Rationale

Integrin αvβ3 is a transmembrane receptor implicated in cell adhesion, migration, and angiogenesis, especially in tumor microenvironments (America Peptide). The RGD (Arg-Gly-Asp) motif, found in extracellular matrix proteins, is a key ligand for αvβ3, facilitating cell-extracellular matrix interactions. Cyclo (-RGDfC) mimics this motif in a cyclic conformation, increasing its receptor affinity and resistance to proteolytic degradation compared to linear RGD peptides. This specificity allows researchers to dissect integrin-dependent pathways in cancer and vascular biology. Targeting αvβ3 integrin is particularly relevant in aggressive cancers, such as osteosarcoma, where integrin expression and signaling contribute to metastasis and angiogenesis (APExBIO). The cyclic structure of Cyclo (-RGDfC) ensures robust performance in complex biological assays and high-throughput screening platforms (Cyclo-RGDfK.com).

Mechanism of Action of Cyclo (-RGDfC)

Cyclo (-RGDfC) acts as a competitive inhibitor or probe for the αvβ3 integrin receptor. The peptide’s RGD motif binds to the ligand-binding pocket of αvβ3, blocking or mimicking natural extracellular matrix ligands such as fibronectin or vitronectin. This binding modulates downstream signaling cascades involved in cell adhesion, migration, proliferation, and survival. By occupying the integrin site, Cyclo (-RGDfC) can inhibit integrin-mediated cell attachment and migration, which are critical in tumor invasion and angiogenic sprouting. The cyclic conformation (c(RGDfC)) further enhances the peptide’s affinity and selectivity, reducing off-target interactions and improving resistance to enzymatic degradation. This mechanism underpins its use in cell adhesion assays, migration studies, and as a targeting vector for drug or nanoparticle conjugation (America Peptides Hydrogel Article).

Evidence & Benchmarks

• Cyclo (-RGDfC) demonstrates high binding affinity to αvβ3 integrin, with dissociation constants (K_d) in the low nanomolar range under physiological conditions (America Peptides).
• The peptide exhibits >98% purity by HPLC and is confirmed by mass spectrometry and NMR for batch reproducibility (APExBIO).
• Solubility exceeds 49 mg/mL in DMSO at 25°C, supporting high-concentration stock preparation for functional assays (APExBIO).
• Cyclo (-RGDfC) resists proteolytic cleavage in serum-containing media for at least 24 hours, outperforming linear RGD peptides (Cyclo-RGDfK.com).
• Validated in integrin-mediated cell adhesion and migration assays, including hydrogel-based platforms and 2D/3D models (America Peptides Hydrogel Article).
• Product is intended strictly for research use and not for diagnostic or medical applications (APExBIO).

Applications, Limits & Misconceptions

Cyclo (-RGDfC) is widely employed in cancer research, angiogenesis studies, and biomaterial engineering. It enables precise interrogation of integrin αvβ3-dependent mechanisms and supports development of targeted delivery systems. The peptide is conjugatable to drugs, proteins (e.g., convistatin), or nanoparticles to enhance tissue-specific targeting. Applications extend to high-throughput hydrogel platforms for screening integrin-mediated cell behaviors (America Peptides Hydrogel Article), and to mechanistic studies of tumor microenvironment interactions.

Common Pitfalls or Misconceptions

• Not suitable for in vivo therapeutic or diagnostic use: Cyclo (-RGDfC) is for research purposes only and lacks regulatory approval for medical applications (APExBIO).
• Not soluble in water or ethanol: Stock solutions must be prepared in DMSO to achieve required concentrations and maintain peptide activity.
• Does not inhibit all integrins: The peptide is highly selective for αvβ3 integrin; effects on other integrin subtypes are limited or absent (America Peptide).
• Stability limitations: Solutions are recommended for short-term use only; long-term storage may cause peptide degradation or loss of activity.
• Proteolytic resistance is relative: While more stable than linear RGD peptides, prolonged incubation in biological fluids may still result in partial degradation.

This article provides mechanistic and workflow guidance beyond the coverage in this America Peptide primer, clarifying conjugation options and experimental boundaries for Cyclo (-RGDfC).

For a practical overview of high-throughput hydrogel applications, see this detailed methods article; the present review expands on peptide stability and workflow integration.

Workflow Integration & Parameters

Cyclo (-RGDfC) is supplied as a lyophilized powder (SKU: A8790; MW 578.64; C₂₄H₃₄N₈O₇S) by APExBIO (product link). The recommended storage condition is -20°C. Solutions should be freshly prepared in DMSO at concentrations ≥49 mg/mL. For cell-based assays, dilute into compatible buffers immediately before use. Peptide can be conjugated to proteins, drugs, or nanoparticles using standard sulfhydryl or amine-reactive chemistries; the presence of a cysteine (C) at the terminus facilitates thiol-specific modifications. Typical working concentrations in cell adhesion studies range from 1–10 μg/mL, but optimization may be required based on assay design. Quality is controlled by HPLC, MS, and NMR, with batch certificates available upon request (APExBIO).

Conclusion & Outlook

Cyclo (-RGDfC) is a validated, high-affinity cyclic peptide that empowers cancer and angiogenesis research by enabling selective targeting of the integrin αvβ3 receptor. Its robust stability, solubility in DMSO, and >98% purity make it a benchmark tool for integrin-mediated cell adhesion, migration, and signaling pathway analysis. APExBIO’s Cyclo (-RGDfC) supports reproducible, high-impact studies across cell biology and biomaterials engineering. Ongoing innovation in conjugation and biomaterial platforms is expected to further extend the utility of this peptide in preclinical research.